Abstract: TH-PO386
Characteristics of the US ESRD Population With Autosomal Dominant Polycystic Kidney Disease
Session Information
- Genetic Diseases of the Kidneys: Cystic - I
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidneys
- 1101 Genetic Diseases of the Kidneys: Cystic
Authors
- Stevanovic, Mirjana, Dartmouth Guarini School of Advanced Studies, Hanover, New Hampshire, United States
- Graber, Martha L., Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, United States
Background
We present recent data concerning US individuals with autosomal dominant polycystic kidney disease (APCKD) and ESRD
Methods
We used data from the US Renal Data System (USRDS) 2014 - 2018 to compare prevalent persons with ESRD and ADPCKD to those without ADPCKD
Results
Persons with ADPCKD (N = 42714) comprised 3.1% of the US ESRD population. APCKD accounted for 99.4 % of all adult cystic disease categories (data not shown).
Persons with ADPCKD were younger on entry to the ESRD program by 4.9 years, more likely to be female and White, to have had nephrology care, to have initiated with peritoneal dialysis or transplant, and to have received a living donor kidney. There was no difference in the risk of death.
Conclusion
The vast majority, 99.4%, of persons with adult cystic diseases on entry to the ESRD program have a diagnosis of APCKD. Those with APCKD comprised 3.1% of the total US ESRD population, a figure consitent with data from the USRDS 1998 annual report, Europe and Japan, but lower than has been commonly reported in the US. We estimate that 3 - 7% of all US persons with APCKD are ion dialysis or have a transplant at any one time.
On entry to the ESRD program individuals with ADPCKD were younger, more likely to be White and female, to have had prior nephrology care, to have initiated renal replacement therapy with peritoneal dialysis or transplant and to have received a living donor graft than those with ESRD without APCKD. There was no significant difference in the risk of death during a five year period.
These findings contribute to our understanding of the epidemiology, risks, and outcomes of APCKD .
Funding
- Other NIH Support